AVOID THE WEEKEND! Study of high-impact rheumatology journals (Rheumatology, J Rheum, & Seminars A&R) shows higher risk of "desk rejections" by editor (avoiding peer review) for manuscripts submitted Saturday (OR 1.23) or Sunday (OR 1.13) https://t.co/8LAymRZBth https://t.co/g5koHHZZaX

VIDEO: No Glory in GLORIA Dr. Richard Conway discusses abstract OP0263 presented at #EULAR2022. https://t.co/tlsTPztYqY https://t.co/5dOma69vLZ

Baricitinib (JAK1/2 inhib) in 10 pts w/ systemic sclerosis showed improvement in modified Rodnan Skin Score ( −11.67 @wk 24; p=0.0008); 3/4 w/ digital ulcers healed at week 24. Similar findings seen in bleomycin induced animal model https://t.co/1G9CGjLK2N https://t.co/Gt35DcMyuz

Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Watch: Demystifying Synovial Tissue Biology Dr. Aurelie Najm ( @AurelieRheumo) discusses abstracts OP0084 and OP0085 presented at #EULAR2022. https://t.co/LNfFmxiE8O https://t.co/aiLvdtxYRB

Malignancy risk on b/tsDMARDs in patients with prior malignancy history For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. https://t.co/cZwJFoqx0C https://t.co/QgoN0Qd5yz

VIDEO: Golden Window in Pre-RA Dr. Richard Conway ( @RichardPAConway) discusses abstract OP0070 presented at #EULAR2022. https://t.co/VoVo4TTgvO https://t.co/7NrZqJlwjo

PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals? POS0309 at #EULAR2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies. https://t.co/8newrxP1hn https://t.co/c9SwrRd8mw

WATCH: Severe Hematologic Relapse Risk in SLE Dr. Kathryn Dao ( @KDAO2011) discusses POS0365 presented at the #EULAR2022 meeting. https://t.co/a0LgsEZ0w4 https://t.co/Ajl22OIHxD

Topical therapies take centre stage Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. #EULAR2022 https://t.co/V9plk1vAEd https://t.co/fyNWWtconi